ENO 3001
Alternative Names: ENO-3001Latest Information Update: 21 Aug 2023
At a glance
- Originator Enochian BioSciences
- Developer Renovaro Biosciences
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 09 Aug 2023 Enochian BioSciences is now called Renovaro Biosciences
- 28 Aug 2022 No recent reports of development identified for preclinical development in Colorectal-cancer(Prevention of relapse) in USA
- 23 Jul 2018 Preclinical trials in Colorectal cancer (Prevention of relapse) in USA (unspecified route)